{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:23:53Z","timestamp":1792578233082,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Inflammatory breast cancer (IBC) is an aggressive variant for which trimodality treatment (ie, neoadjuvant systemic therapy [NST] followed by modified radical mastectomy without immediate reconstruction and postmastectomy radiotherapy [PMRT]) represents guideline-concordant care (GCC) and is associated with improved overall survival (OS). However, it is unclear whether there are disparities in trimodality treatment receipt among patients with IBC and how such disparities might affect OS.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess trends in IBC trimodality treatment receipt in a contemporary cohort.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A retrospective cohort study was conducted using data from the National Cancer Database. Women with nonmetastatic IBC treated from calendar years 2010 to 2018 were included. Data analysis was performed from April 1, 2023, to March 1, 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Guideline-concordant care (ie, trimodality treatment administered in the correct sequence with time to NST initiation &amp;lt;60 days post diagnosis).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were associations between patient-, disease-, treatment-, and facility-level factors and receipt of overall and modality-specific GCC and associations between these factors and adjusted OS.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 6945 patients identified (median age, 57 [IQR, 47-66] years; 2.4% Asian or Pacific Islander, 7.8% Hispanic, 17.1% non-Hispanic Black, and 71.5% non-Hispanic White), only 1740 (25.1%) received all forms of GCC: 91.3% (n\u2009=\u20095662) received NST initiation less than 60 days post diagnosis, 63.3% (n\u2009=\u20094395) received PMRT, and 51.3% (n\u2009=\u20093564) underwent guideline-concordant surgery (ie, modified radical mastectomy without immediate reconstruction with &amp;gt;6 lymph nodes removed). Receipt of GCC did not differ significantly by race and ethnicity, insurance status, or location. Asian (odds ratio [OR], 0.48; 95% CI, 0.27-0.84), Black (OR, 0.53; 95% CI, 0.41-0.68), and Hispanic (OR, 0.40; 95% CI, 0.29-0.55) patients were less likely to have NST initiation less than 60 days post diagnosis vs White patients (all P<\/jats:italic>\u2009\u2264\u2009.001). Recipients of GCC had improved adjusted OS vs nonrecipients (hazard ratio [HR], 0.75; 95% CI, 0.68-0.84; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Black patients had significantly lower adjusted OS ,compared with White recipients (HR, 1.41; 95% CI, 1.26-1.58; P<\/jats:italic>\u2009&amp;lt;\u2009.001). When GCC was received for triple-negative IBC, there was no racial and ethnic disparity in OS.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of women with nonmetastatic IBC, there were no disparities observed in GCC receipt, but only 25.1% of patients with IBC received all forms of GCC for which they were eligible. Among those who received GCC, there was no racial disparity in survival for triple-negative IBC, suggesting opportunities to improve equity through standardization of care.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.54506","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:32:41Z","timestamp":1740587561000},"page":"e2454506","source":"Crossref","is-referenced-by-count":17,"title":["Trends in Guideline-Concordant Care for Inflammatory Breast Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Audree","family":"Tadros","sequence":"first","affiliation":[{"name":"Breast Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Diskin","sequence":"additional","affiliation":[{"name":"Breast Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Now with Saint John\u2019s Cancer Institute, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[{"name":"Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perri","family":"Vingan","sequence":"additional","affiliation":[{"name":"Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Nelson","sequence":"additional","affiliation":[{"name":"Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[{"name":"Breast Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwadamilola M.","family":"Fayanju","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia"},{"name":"Rena Rowan Breast Center, Abramson Cancer Center, Penn Medicine, Philadelphia, Pennsylvania"},{"name":"Penn Center for Cancer Care Innovation, Abramson Cancer Center, Philadelphia, Pennsylvania"},{"name":"Leonard Davis Institute of Health Economics, The University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"6","key":"zoi241528r1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.1992.10.6.1014","article-title":"Inflammatory breast cancer: a review.","volume":"10","author":"Jaiyesimi","year":"1992","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi241528r2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi241528r3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"zoi241528r4","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1245\/s10434-023-13906-5","article-title":"Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy.","volume":"30","author":"Adesoye","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi241528r5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"zoi241528r6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","article-title":"Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.","volume":"32","author":"Rueth","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi241528r7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-023-07018-7","article-title":"Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.","volume":"201","author":"Carbajal-Ochoa","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi241528r8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10549-018-5037-y","article-title":"Racial\/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.","volume":"173","author":"Gudina","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"zoi241528r9","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7574946","article-title":"Racial and socioeconomic disparities are more pronounced in inflammatory breast cancer than other breast cancers.","volume":"2017","author":"Denu","year":"2017","journal-title":"J Cancer Epidemiol"},{"key":"zoi241528r10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.breast.2017.06.002","article-title":"A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: a large population-based study in the Surveillance, Epidemiology, and End Results database 18.","volume":"35","author":"Chen","year":"2017","journal-title":"Breast"},{"issue":"13","key":"zoi241528r11","doi-asserted-by":"publisher","first-page":"8789","DOI":"10.1245\/s10434-021-10404-4","article-title":"Immediate breast reconstruction for inflammatory breast cancer: trends in use and clinical outcomes 2004-2016.","volume":"28","author":"Hoffman","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"zoi241528r12","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1245\/s10434-022-12408-0","article-title":"Contemporary trends in breast reconstruction use and impact on survival among women with inflammatory breast cancer.","volume":"29","author":"Nair","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"zoi241528r13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11788-7","article-title":"Immediate breast reconstruction in inflammatory breast cancer: are we there yet?","author":"Adesoye","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"7624","key":"zoi241528r14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"zoi241528r19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.surg.2021.08.061","article-title":"Inflammatory breast cancer, trimodal treatment, and mortality: does where you live matter?","volume":"171","author":"Relation","year":"2022","journal-title":"Surgery"},{"issue":"14","key":"zoi241528r20","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/cncr.30660","article-title":"Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.","volume":"123","author":"Lin","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"zoi241528r21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-019-05219-7","article-title":"Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.","volume":"176","author":"van Uden","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"zoi241528r22","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1245\/s10434-017-5952-x","article-title":"Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery.","volume":"24","author":"Rosso","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"zoi241528r23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-020-05938-2","article-title":"Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.","volume":"185","author":"Abraham","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi241528r24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ijrobp.2012.01.030","article-title":"Modern outcomes of inflammatory breast cancer.","volume":"84","author":"Rehman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"zoi241528r25","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/cncr.25682","article-title":"Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.","volume":"117","author":"Dawood","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"zoi241528r26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi241528r27","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1245\/s10434-017-5903-6","article-title":"The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer.","volume":"24","author":"Nakhlis","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"zoi241528r28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2018-0677","article-title":"Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.","volume":"15","author":"Wu","year":"2019","journal-title":"Future Oncol"},{"issue":"8","key":"zoi241528r29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/bjs.11469","article-title":"Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.","volume":"107","author":"Kupstas","year":"2020","journal-title":"Br J Surg"},{"issue":"4","key":"zoi241528r30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5152\/ejbh.2018.4170","article-title":"The impact of subtype distribution in inflammatory breast cancer outcome.","volume":"14","author":"\u00c7akar","year":"2018","journal-title":"Eur J Breast Health"},{"issue":"1","key":"zoi241528r31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00432-016-2281-6","article-title":"Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.","volume":"143","author":"Liu","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"zoi241528r32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1634\/theoncologist.2019-0744","article-title":"Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast cancer.","volume":"25","author":"de Melo Gagliato","year":"2020","journal-title":"Oncologist"},{"issue":"24","key":"zoi241528r33","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1002\/cncr.26187","article-title":"Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?","volume":"117","author":"Andic","year":"2011","journal-title":"Cancer"},{"key":"zoi241528r34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1245\/s10434-016-5554-z","article-title":"Immediate reconstruction in inflammatory breast cancer: challenging current care.","volume":"23","author":"Simpson","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"zoi241528r35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jamcollsurg.2021.04.016","article-title":"Reconstruction in women with T4 breast cancer after neoadjuvant chemotherapy: when is it safe?","volume":"233","author":"Pawloski","year":"2021","journal-title":"J Am Coll Surg"},{"issue":"3","key":"zoi241528r36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/tbj.13509","article-title":"Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: the Dana-Farber Cancer Institute\u2019s Inflammatory Breast Cancer Program experience.","volume":"26","author":"Nakhlis","year":"2020","journal-title":"Breast J"},{"issue":"1","key":"zoi241528r37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10549-020-05529-1","article-title":"Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.","volume":"180","author":"Fayanju","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"zoi241528r38","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","article-title":"Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer.","volume":"18","author":"DeSnyder","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"zoi241528r39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF02573060","article-title":"Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.","volume":"9","author":"Stearns","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi241528r40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer.","volume":"7","author":"Hidar","year":"2009","journal-title":"Int J Surg"},{"issue":"2","key":"zoi241528r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48021","article-title":"Trends in sentinel lymph node biopsies in patients with inflammatory breast cancer in the US.","volume":"5","author":"Sosa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi241528r42","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1245\/s10434-020-08891-y","article-title":"Factors associated with pathological node negativity in inflammatory breast cancer: are there patients who may be candidates for a de-escalation of axillary surgery?","volume":"27","author":"Postlewait","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi241528r45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.prro.2019.05.011","article-title":"Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach.","volume":"9","author":"Stecklein","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"zoi241528r46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.seminoncol.2007.11.009","article-title":"The role of locoregional therapy in inflammatory breast cancer.","volume":"35","author":"Woodward","year":"2008","journal-title":"Semin Oncol"},{"issue":"4","key":"zoi241528r47","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ijrobp.2016.02.065","article-title":"Disparities in the use of postmastectomy radiation therapy for inflammatory breast cancer.","volume":"95","author":"Loveland-Jones","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"zoi241528r48","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1245\/s10434-022-12237-1","article-title":"Guideline-consistent treatment for inflammatory breast cancer provides associated survival benefit independent of age.","volume":"29","author":"Drapalik","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi241528r49","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1245\/s10434-021-10453-9","article-title":"Inflammatory breast cancer at the extremes of age.","volume":"28","author":"Adesoye","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"zoi241528r17","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2016","edition":"8th ed"},{"key":"zoi241528r15","unstructured":"Commission on Cancer. Facility Oncology Registry Data Standards. January 1, 2016. Accessed December 17, 2024. https:\/\/www.facs.org\/media\/r5rl5scw\/fords-2016.pdf"},{"key":"zoi241528r16","unstructured":"US Dept of Agriculture Economic Research Service. Rural-urban continuum codes. Accessed January 22, 2024. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes\/documentation\/#referencedate"},{"key":"zoi241528r18","unstructured":"Commission on Cancer. Accreditation. American College of Surgeons. Accessed April 24, 2024. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/commission-on-cancer\/coc-accreditation\/"},{"key":"zoi241528r43","unstructured":"Sentinel lymph node biopsy after neoadjuvant chemotherapy for locally advanced breast cancer. ClinicalTrials.gov identifier: NCT03255577. July 7, 2024. Accessed November 18, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03255577"},{"key":"zoi241528r44","unstructured":"Refining local-regional therapy for IBC. ClinicalTrials.gov identifier: NCT04636710. December 19, 2023. Accessed November 18, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04636710"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830765\/tadros_2025_oi_241528_1739997010.14684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:32:47Z","timestamp":1740587567000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54506","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}